December 20, 2018 / 12:49 PM / a month ago

Gilead, Agenus sign deal to develop immuno-oncology therapies

Dec 20 (Reuters) - Gilead Sciences Inc has inked a collaboration agreement with Agenus Inc for the development and marketing of up to five novel immuno-oncology therapies.

Agenus will get an upfront cash payment of $120 million and a $30 million equity investment, and will also be eligible to receive about $1.7 billion in potential future fees and milestones, the companies said in a statement on Thursday. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below